ストックスクリーナーアプリを入手
14.86
0.87%
-0.13
アフターアワーズ：
14.87
0.010
+0.07%
Bausch Lomb Corp (BLCO) 最新ニュース
Bausch + Lomb Corporation (BLCO): Investor Outlook With An 18.53% Potential Upside - DirectorsTalk Interviews
Bausch + Lomb to lay off employees in Missouri - Yahoo Finance
Transcript : Bausch + Lomb Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01 - marketscreener.com
Bausch + Lomb Dry Eye Launch Highlights Valuation Gap And Growth Questions - Yahoo Finance
Why Bausch + Lomb Corp stock is sliding today - Wealth Awesome
Bausch + Lomb Corporation (BLCO): Investor Outlook and Potential 15.62% Upside in the Healthcare Sector - DirectorsTalk Interviews
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch - Sahm
Will Blink Triple Care’s Preservative Free Launch Reshape Bausch + Lomb’s (BLCO) Consumer Eye Care Narrative? - webull.com
Bausch + Lomb’s New Dry Eye Launch And What It Means For BLCO - Sahm
RBC Capital reiterates Bausch & Lomb stock rating at Outperform By Investing.com - Investing.com Australia
RBC Capital reiterates Bausch & Lomb stock rating at Outperform - Investing.com
Bausch + Lomb Corp stock (CA07174N1090): valuation metrics in focus after recent trading in Toronto - AD HOC NEWS
Liquidity Mapping Around (BLCO) Price Events - Stock Traders Daily
Bausch + Lomb Corp. Price Target Is Maintained at $19.00/Share by Citi - Moomoo
BLCO.CA Stock Price, Quote & Chart | BAUSCH + LOMB CORP (TSX:BLCO) - ChartMill
Bausch + Lomb launches preservative-free dry eye drops in U.S. By Investing.com - Investing.com South Africa
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States - BioSpace
Preservative-free eye drops offer up to 10 hours dry-eye relief - Stock Titan
Bausch + Lomb Corporation (BLCO) Investor Outlook: Analyzing Growth Potential with a 14% Upside - DirectorsTalk Interviews
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch & Lomb (BLCO) director awarded 15,842 RSUs under 2022 Omnibus Incentive Plan - Stock Titan
Bausch & Lomb (NYSE: BLCO) grants 15,842 RSUs to director - Stock Titan
Bausch & Lomb (NYSE: BLCO) director awarded 15,842-share RSU grant - Stock Titan
Bausch & Lomb (BLCO) director John Paulson receives 15,842-share RSU grant - Stock Titan
Bausch & Lomb (BLCO) director Karen Ling awarded 15,842 RSUs as annual equity grant - Stock Titan
Director at Bausch & Lomb (NYSE: BLCO) gets 15,842-share RSU award - Stock Titan
Bausch & Lomb Corp (BLCO) awards 15,842 RSUs to director Collis - Stock Titan
Bausch & Lomb (BLCO) director granted 15,842 RSUs in annual equity award - Stock Titan
Bausch & Lomb (NYSE: BLCO) director receives 15,842-share RSU grant - Stock Titan
Bausch + Lomb Lifts 2026 Guidance, 1Q Loss Narrows - Moomoo
Bausch & Lomb (NYSE: BLCO) CEO reports 2,886-share tax withholding on RSU vesting - Stock Titan
Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher (NYSE:BLCO) - Seeking Alpha
Evercore ISI Group Maintains Bausch + Lomb (BLCO) Outperform Recommendation - MSN
Bausch + Lomb Corporation (BLCO) Stock Analysis: Unpacking a Potential 13% Upside for Investors - DirectorsTalk Interviews
Brent Saunders: Healthcare Innovation Leader, Global Pharmaceutical Executive, and Bausch + Lomb CEO - BBN Times
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - BioSpace
Medical Devices & SuppliesSpecialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest - Yahoo Finance
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb CEO, R&D chief to join Goldman Sachs health-care chat - Stock Titan
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results - BioSpace
Board re-elected, exec pay backed: inside Bausch + Lomb’s 2026 vote - Stock Titan
Bausch + Lomb (BLCO) investors approve board, pay and PwC auditor at 2026 meeting - Stock Titan
Bausch + Lomb unveils PreserVision AREDS3 eye vitamins in the U.S. - Mass Market Retailers
New eye vitamin targets leading cause of vision loss in older Americans - Stock Titan
Bausch + Lomb Corporation (BLCO) Stock Analysis: Exploring the 12% Upside Potential in Eye Health - DirectorsTalk Interviews
How Investors May Respond To Bausch + Lomb (BLCO) Surgical Launch and EBITDA Momentum - Yahoo Finance
Bausch + Lomb Corporation (BLCO): Carl C. Icahn Likes This Stock - Insider Monkey
Bausch + Lomb launches advanced dual-port vitrectomy cutter in Europe - Ophthalmology Times Europe
5.23%
大文字化:
|
ボリューム (24 時間):